LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma, announced today the appointment of Vladimir Morozov, Ph.D., as Senior Director of Bioinformatics. In this position, Vladimir will focus on identifying interesting collaborators for LEO, scope out research and acceleration activities, run collaborative projects and guide development towards dermatological use-cases.
Vladimir brings over 25 years of experience in business and academia. His work has focused heavily on genomic data design and analysis, with recent emphasis on machine and deep-learning methods.
Prior to joining LEO Science & Tech Hub, Vladimir served as a Bioinformatics Solution Architect at Shire, where he built machine-learning methods to optimize antibody activity and worked with wearable technologies to identify digital biomarkers for patients with Parkinsons disease and Chronic fatigue syndrome (CFS). Prior to that, he served as a Senior Computational Biology Scientist at ALS Therapy Development Institute where he established Next-Generation Sequencing (NGS) and predictive models from patient data. He has also held positions at Dana-Farber Cancer Institute and LION Bioscience, Inc. Vladimir earned a Ph.D. in Chemical Enzymology from Moscow State University.
Michael Sierra, Vice President of LEO Science & Tech Hub commented: With so much of our current research focused on developing new methods for biomarker discovery and analysis, Vladimir is truly a natural addition to our team. We are excited by the continued growth of our Boston office and will look to Vladimir to help drive the direction of a number of our early-stage projects.
Vladimir Morozov, Senior Director of Bioinformatics at LEO Science & Tech Hub stated: LEO Pharma continues to serve as a strong example of how to prioritize innovation in science and technology to improve patient outcomes. The Science & Tech Hubs unique model allows our team to pursue cutting-edge projects with disruptive potential. I look forward to leveraging my background to have a positive impact on the organization.
About LEO Science & Tech Hub
The LEO Science & Tech Hub is an R&D innovation unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases. It was founded in 2016 as a catalyst to transform early-stage innovations into solutions for improving the lives of people with skin diseases. We collaborate, explore cutting-edge ideas and make investments. We are an agile group of scientific experts with an entrepreneurial mindset and a vision of how to give patients control over disease by predicting, diagnosing, and monitoring conditions. The LEO Science & Tech Hub is based in Cambridge, Mass. For more information, please visit www.leo-scitech.com, or connect with us at [email protected], on Twitter @LEOscitech or LinkedIn www.linkedin.com/company/leo-science-&-tech-hub/
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,700 people, serving 80 million patients in 130 countries. In 2017, the company generated net sales of 1.4 billion euro.
Alex Ignatius Costa
LEO Science & Tech Hub
374-8800 ext. 104